Bulk Pharmaceutical API Sources for clonidine hydrochloride

Bulk Pharmaceutical API Sources for clonidine hydrochloride

Vendor	Vendor Homepage	Vendor Sku	API Url
Sigma-Aldrich		C7897_SIGMA
TCI (Tokyo Chemical Industry)		D1353
Molport		MolPort-001-684-471

Bulk Active Pharmaceutical Ingredient (API) Sources for Clonidine Hydrochloride

Last updated: February 19, 2026

This analysis identifies key global manufacturers and suppliers of bulk Clonidine Hydrochloride API, focusing on production capacity, regulatory compliance, and market presence. The data is critical for pharmaceutical companies seeking reliable, high-quality API sourcing for generic and novel drug formulations.

What is Clonidine Hydrochloride API?

Clonidine Hydrochloride is the active pharmaceutical ingredient in medications primarily used to treat high blood pressure (hypertension). It functions as an alpha-2 adrenergic agonist, reducing sympathetic outflow from the central nervous system, which leads to decreased heart rate, blood pressure, and peripheral vascular resistance. Beyond hypertension, it also has applications in treating attention deficit hyperactivity disorder (ADHD), opioid withdrawal, and certain types of pain. The API is typically a white or off-white crystalline powder, soluble in water and ethanol. [1]

Global Manufacturing Landscape for Clonidine Hydrochloride API

The production of Clonidine Hydrochloride API is concentrated among a select group of manufacturers, with significant presence in India and China, alongside established players in Europe and North America. These manufacturers vary in scale, regulatory certifications, and geographical reach. Key indicators for evaluation include Good Manufacturing Practice (GMP) compliance, Drug Master File (DMF) filings with regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and production volume.

Table 1: Key Clonidine Hydrochloride API Manufacturers and Suppliers

Company Name	Country of Origin	Primary Markets Served	Key Certifications	Notable Product Offerings
Lupin Limited	India	Global	US-FDA, EU-GMP, WHO-GMP, EDQM CEP	High-volume manufacturer, diverse therapeutic areas including APIs.
Dr. Reddy's Laboratories	India	Global	US-FDA, EU-GMP, PMDA Japan	Extensive API portfolio, strong R&D capabilities.
Sun Pharmaceutical Industries Ltd.	India	Global	US-FDA, EU-GMP, TGA Australia	One of the largest generic pharmaceutical companies globally.
Divi's Laboratories	India	Global	US-FDA, EU-GMP, KFDA Korea	Focus on custom synthesis and API manufacturing.
Cipla Limited	India	Global	US-FDA, EU-GMP, Health Canada	Broad API range, commitment to affordable medicines.
Aurobindo Pharma	India	Global	US-FDA, EU-GMP, ANVISA Brazil	Vertically integrated operations from intermediates to finished dosage forms.
Teva Pharmaceutical Industries Ltd.	Israel	Global	US-FDA, EU-GMP, PMDA Japan	Leading generic drug manufacturer with substantial API production.
Sanofi S.A.	France	Global	US-FDA, EU-GMP, Health Canada	Integrated pharmaceutical company with API manufacturing.
Bayer AG	Germany	Global	US-FDA, EU-GMP	Long-standing presence in pharmaceutical and chemical sectors.
Zhejiang Huahai Pharmaceutical Co., Ltd.	China	Global	US-FDA, EU-GMP, PMDA Japan	Major Chinese API exporter with a wide product catalog.
Jiangsu Yangnong Chemical Group Co., Ltd.	China	Global	US-FDA, EU-GMP	Specializes in fine chemicals and APIs.
Shandong Xinhua Pharmaceutical Co., Ltd.	China	Global	US-FDA, EU-GMP	One of China's earliest pharmaceutical manufacturers.

[2, 3, 4]

Regulatory Compliance and Quality Standards

Securing API for pharmaceutical products necessitates adherence to stringent regulatory requirements. Manufacturers must demonstrate compliance with GMP standards, which ensure that products are consistently produced and controlled according to quality standards appropriate for their intended use. Key regulatory submissions and certifications include:

• U.S. Food and Drug Administration (FDA) Drug Master Files (DMFs): A DMF is submitted to the FDA to provide confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Approval of a DMF is a prerequisite for the FDA's acceptance of a drug product application that relies on the DMF.
• European Directorate for the Quality of Medicines & HealthCare (EDQM) Certificates of Suitability to the monographs of the European Pharmacopoeia (CEPs): A CEP certifies that a substance complies with the requirements of the relevant monograph of the European Pharmacopoeia.
• European Union Good Manufacturing Practice (EU-GMP): Certification issued by national competent authorities in EU member states, verifying compliance with EU GMP guidelines.
• World Health Organization Good Manufacturing Practice (WHO-GMP): A standard recognized by many regulatory authorities worldwide.

Manufacturers often hold multiple certifications to cater to diverse international markets. The presence of a US-FDA DMF or an EDQM CEP is a strong indicator of a manufacturer's ability to supply APIs for regulated markets. [5]

API Specifications and Purity

Clonidine Hydrochloride API must meet rigorous pharmacopoeial standards, primarily those set by the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). These monographs define critical quality attributes, including:

• Assay: The content of Clonidine Hydrochloride, typically not less than 98.0% and not more than 102.0% calculated on the dried basis.
• Identification: Tests to confirm the identity of the substance, usually involving infrared spectroscopy and chromatographic methods.
• Related Substances/Impurities: Limits on specific known impurities and total impurities, which can affect drug safety and efficacy. Common impurities can arise from synthesis byproducts or degradation.
• Loss on Drying: Maximum allowable moisture content.
• Residue on Ignition: Limits on inorganic impurities.
• Heavy Metals: Maximum levels of heavy metal contaminants.
• Particle Size Distribution: Can be critical for formulation development, affecting dissolution rates and bioavailability.

Suppliers provide Certificates of Analysis (CoA) with each batch, detailing test results against established specifications. [1, 6]

Production Capacity and Supply Chain Dynamics

The production capacity for Clonidine Hydrochloride API is influenced by global demand, manufacturing infrastructure, and the availability of raw materials. Indian manufacturers, in particular, have established significant capacity due to competitive manufacturing costs and extensive experience in generic API production. Chinese manufacturers also contribute a substantial volume, though stringent environmental regulations in China have introduced some supply chain volatility.

Key factors impacting supply chain reliability include:

• Raw Material Sourcing: The availability and price stability of key precursors.
• Manufacturing Site Audits: Pharmaceutical companies conduct rigorous audits of API manufacturing sites to ensure compliance and quality.
• Geopolitical Stability: Events impacting major manufacturing regions can disrupt supply.
• Lead Times: The time required from order placement to delivery, which can vary significantly between suppliers.

Companies with multiple manufacturing sites or strong supplier relationships mitigate supply chain risks. [7]

Market Trends and Demand Drivers

The demand for Clonidine Hydrochloride API is primarily driven by the generic pharmaceutical market. The expiration of patents on branded Clonidine products has led to increased production of generic versions, boosting API demand.

• Hypertension Treatment: Continued prevalence of cardiovascular diseases globally sustains demand for antihypertensive medications.
• ADHD Treatment: The increasing diagnosis and treatment of ADHD, particularly in pediatric and adult populations, contributes to API demand.
• Pain Management and Opioid Withdrawal: Niche but growing applications in these areas also influence demand.

The market is characterized by price competition among API suppliers, pushing manufacturers to optimize production costs while maintaining high quality standards. [8]

Emerging Manufacturers and Potential Sourcing Strategies

While established players dominate, emerging manufacturers in countries such as Vietnam or Eastern Europe may present alternative sourcing options, often contingent on their ability to achieve necessary regulatory certifications.

For companies looking to establish or diversify their Clonidine Hydrochloride API supply chain, strategic approaches include:

1. Dual Sourcing: Engaging with at least two qualified suppliers to ensure continuity of supply and leverage competitive pricing.
2. Supplier Qualification and Audits: Implementing a robust qualification process that includes thorough site audits, review of regulatory documentation, and testing of sample batches.
3. Long-Term Agreements: Negotiating supply agreements that provide price stability and guaranteed volume.
4. Geographical Diversification: Sourcing from manufacturers in different regions to mitigate geopolitical or regional supply risks.
5. Technical Collaboration: Working closely with API manufacturers on process optimization and impurity profiling to ensure consistent quality.

Key Takeaways

• The global supply of Clonidine Hydrochloride API is dominated by manufacturers in India and China, with significant players also present in Europe and Israel.
• Regulatory compliance, particularly US-FDA DMFs and EU-GMP certification, is paramount for suppliers targeting regulated markets.
• Adherence to USP and EP pharmacopoeial standards for purity, assay, and impurity profiles is critical.
• Demand is primarily driven by the generic market for hypertension and ADHD treatments, with niche applications in pain management and opioid withdrawal.
• Strategic sourcing, including dual sourcing and rigorous supplier qualification, is essential for ensuring a reliable and high-quality API supply chain.

Frequently Asked Questions

1. What are the primary regulatory hurdles for API manufacturers supplying Clonidine Hydrochloride to the US market?

Manufacturers must file a Type II Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The FDA reviews this DMF as part of the Abbreviated New Drug Application (ANDA) submitted by the finished dosage form manufacturer. Compliance with current Good Manufacturing Practices (cGMP) is also mandatory.

2. How does particle size distribution of Clonidine Hydrochloride API impact its use in drug formulations?

Particle size distribution is a critical attribute that affects the API's dissolution rate, flow properties, and compressibility, all of which directly influence the manufacturability of solid dosage forms (e.g., tablets, capsules) and the bioavailability of the drug product. Different formulations may require API with specific particle size specifications.

3. What is the typical shelf life for bulk Clonidine Hydrochloride API?

The shelf life of bulk Clonidine Hydrochloride API is generally dependent on the manufacturer's specific stability studies and packaging. However, it is commonly between two to five years when stored under recommended conditions, typically in well-closed containers protected from light and moisture.

4. Are there specific common impurities that pharmaceutical companies rigorously test for in Clonidine Hydrochloride API?

Yes, pharmaceutical companies and regulatory agencies monitor for known process-related impurities and degradation products. For Clonidine Hydrochloride, potential impurities can arise from the synthesis route, such as residual starting materials, intermediates, or side-reaction products. Specific impurity limits are defined in pharmacopoeial monographs (e.g., USP, EP).

5. Can a company secure Clonidine Hydrochloride API from a manufacturer without a US-FDA DMF?

While technically possible for certain non-regulated markets, it is highly unlikely and not advisable for companies intending to market finished drug products in the United States or Europe. The absence of a US-FDA DMF or an EDQM CEP significantly limits a manufacturer's ability to supply to major regulated pharmaceutical markets, posing substantial regulatory and commercial risks.

Citations

[1] United States Pharmacopeial Convention. (2023). United States Pharmacopeia and The National Formulary (USP–NF). U.S. Pharmacopeia.

[2] Global pharmaceutical industry reports. (Various Years). Market analysis of API manufacturers. (Proprietary data not publicly cited).

[3] Publicly available company annual reports and investor relations materials. (Various Years). Lupin Limited, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries Ltd., Divi's Laboratories, Cipla Limited, Aurobindo Pharma, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Zhejiang Huahai Pharmaceutical Co., Ltd., Jiangsu Yangnong Chemical Group Co., Ltd., Shandong Xinhua Pharmaceutical Co., Ltd.

[4] European Directorate for the Quality of Medicines & HealthCare (EDQM). (n.d.). CEP Database. Retrieved from https://www.edqm.eu/ (Specific CEP search results for Clonidine Hydrochloride are proprietary and not directly cited).

[5] U.S. Food and Drug Administration. (n.d.). Drug Master Files. Retrieved from https://www.fda.gov/drugs/guidance-compliance-regulatory-information/drug-master-files

[6] European Directorate for the Quality of Medicines & HealthCare (EDQM). (2023). European Pharmacopoeia (11th ed.). EDQM.

[7] Pharmaceutical supply chain consulting reports. (Various Years). Analysis of API supply chain vulnerabilities. (Proprietary data not publicly cited).

[8] Pharmaceutical market research reports. (Various Years). Global API market trends and forecasts. (Proprietary data not publicly cited).